Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Evolus Inc
(NQ:
EOLS
)
11.77
+0.09 (+0.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
314,575
Open
11.86
Bid (Size)
11.12 (5)
Ask (Size)
12.24 (5)
Prev. Close
11.68
Today's Range
11.68 - 11.98
52wk Range
7.110 - 15.43
Shares Outstanding
54,576,156
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Evolus Announces Appointment of Albert G. White III to Board of Directors
July 01, 2024
From
Evolus
Via
Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
June 24, 2024
From
Evolus
Via
Business Wire
Performance
YTD
+17.82%
+17.82%
1 Month
+2.08%
+2.08%
3 Month
-2.65%
-2.65%
6 Month
+11.56%
+11.56%
1 Year
+54.87%
+54.87%
More News
Read More
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
June 12, 2024
From
Evolus
Via
Business Wire
Evolus: Chiseling Away At The Aesthetic Market
May 25, 2024
Via
Talk Markets
Recap: Evolus Q4 Earnings
March 07, 2024
Via
Benzinga
Earnings Outlook For Evolus
March 06, 2024
Via
Benzinga
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Evolus
Via
Business Wire
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
May 20, 2024
From
Evolus
Via
Business Wire
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
May 15, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Evolus
Via
Business Wire
Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
May 10, 2024
From
Evolus, Inc.
Via
Business Wire
EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Evolus Reports First Quarter 2024 Results and Provides Business Update
May 07, 2024
From
Evolus
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
May 02, 2024
Via
InvestorPlace
Evolus to Report First Quarter Financial Results on May 7, 2024
April 23, 2024
From
Evolus
Via
Business Wire
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
April 17, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
From
Evolus
Via
Business Wire
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Evolus
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
March 21, 2024
Via
Benzinga
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
March 11, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Evolus
Via
Business Wire
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
March 07, 2024
Via
InvestorPlace
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
March 07, 2024
From
Evolus
Via
Business Wire
Earnings Scheduled For March 7, 2024
March 07, 2024
Via
Benzinga
Evolus Announces Results from European Head-to-Head Filler Trial
March 01, 2024
From
Evolus
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.